The phase 1 clinical trial in patients with gene IDH1-mutated gliomas (NCT03030066) showed good tolerance with favorable brain distribution [141]; current work has determined the recommended dose for the phase 2 trial. The gene discussed is IDH1; the disease is central nervous system cancer.